At cellular level we found that ATR inhibition by AZ-20 resulted in more than 10-fold increased etoposide sensitivity in p53 null and p53R273H expressing cells at doses (10 μM) closely related to the ones reported in serum (5–8 μM) of cancer patients treated orally with etoposide [44]. This evidence concerns the gene TP53 and cancer.